ArticleThe Journal of pharmacology and experimental therapeutics2023
In Vivo Pharmacokinetic and Pharmacodynamic Properties of the Antiarrhythmic Molecule
Open access · greenAbstract read
In one paragraph
Article in The Journal of pharmacology and experimental therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 13 citations in OpenAlex.
- Selective RyR2 inhibition reduces arrhythmia susceptibility in human cardiac slices.The Journal of physiology · 2026Article
- Introduction of a single carboxylic acid converts the cyclic oligomeric depsipeptide ent-verticilide from a ryanodine receptor 2 (RyR2) inhibitor to RyR2 activator.Molecular pharmacology · 2025Article
- End-to-End Backbone Cyclization Enhances Passive Permeability of bRo5 Oligomeric Depsipeptides with Nonlinear Size Dependence.ACS medicinal chemistry letters · 2025Article
- Catecholaminergic Polymorphic Ventricular Tachycardia: Advancing From Molecular Insights to Preclinical Models.Journal of the American Heart Association · 2025Review
- Backbone-Determined Antiarrhythmic Structure-Activity Relationships for a Mirror Image, Oligomeric Depsipeptide Natural Product.Journal of medicinal chemistry · 2024Article
- Article
- The selective RyR2 inhibitor ent-verticilide suppresses atrial fibrillation susceptibility caused by Pitx2 deficiency.Journal of molecular and cellular cardiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Daniel J BlackwellDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (D.J.B., J.S., B.C.K.); Departments of Chemistry (A.N.S., J.N.J.) and Pharmacology (A.G., W.S.A), and Vanderbilt Institute of Chemical Biology (A.N.S., J.N.J.), Vanderbilt University, Nashville, Tennessee; Pharmaceutical Sciences Research Center, Lipscomb University, Nashville, Tennessee (T.D., W.S.A); and Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.).
Abigail N SmithDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (D.J.B., J.S., B.C.K.); Departments of Chemistry (A.N.S., J.N.J.) and Pharmacology (A.G., W.S.A), and Vanderbilt Institute of Chemical Biology (A.N.S., J.N.J.), Vanderbilt University, Nashville, Tennessee; Pharmaceutical Sciences Research Center, Lipscomb University, Nashville, Tennessee (T.D., W.S.A); and Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.).
Tri DoDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (D.J.B., J.S., B.C.K.); Departments of Chemistry (A.N.S., J.N.J.) and Pharmacology (A.G., W.S.A), and Vanderbilt Institute of Chemical Biology (A.N.S., J.N.J.), Vanderbilt University, Nashville, Tennessee; Pharmaceutical Sciences Research Center, Lipscomb University, Nashville, Tennessee (T.D., W.S.A); and Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.).
Aaron GochmanDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (D.J.B., J.S., B.C.K.); Departments of Chemistry (A.N.S., J.N.J.) and Pharmacology (A.G., W.S.A), and Vanderbilt Institute of Chemical Biology (A.N.S., J.N.J.), Vanderbilt University, Nashville, Tennessee; Pharmaceutical Sciences Research Center, Lipscomb University, Nashville, Tennessee (T.D., W.S.A); and Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.).
Jeffrey SchmeckpeperDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (D.J.B., J.S., B.C.K.); Departments of Chemistry (A.N.S., J.N.J.) and Pharmacology (A.G., W.S.A), and Vanderbilt Institute of Chemical Biology (A.N.S., J.N.J.), Vanderbilt University, Nashville, Tennessee; Pharmaceutical Sciences Research Center, Lipscomb University, Nashville, Tennessee (T.D., W.S.A); and Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.).
Corey R HopkinsDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (D.J.B., J.S., B.C.K.); Departments of Chemistry (A.N.S., J.N.J.) and Pharmacology (A.G., W.S.A), and Vanderbilt Institute of Chemical Biology (A.N.S., J.N.J.), Vanderbilt University, Nashville, Tennessee; Pharmaceutical Sciences Research Center, Lipscomb University, Nashville, Tennessee (T.D., W.S.A); and Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.).
Wendell S AkersDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (D.J.B., J.S., B.C.K.); Departments of Chemistry (A.N.S., J.N.J.) and Pharmacology (A.G., W.S.A), and Vanderbilt Institute of Chemical Biology (A.N.S., J.N.J.), Vanderbilt University, Nashville, Tennessee; Pharmaceutical Sciences Research Center, Lipscomb University, Nashville, Tennessee (T.D., W.S.A); and Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.) bjorn.knollmann@vanderbilt.edu jeffrey.n.johnston@vanderbilt.edu scott.akers@lipscomb.edu.
Jeffrey N JohnstonDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (D.J.B., J.S., B.C.K.); Departments of Chemistry (A.N.S., J.N.J.) and Pharmacology (A.G., W.S.A), and Vanderbilt Institute of Chemical Biology (A.N.S., J.N.J.), Vanderbilt University, Nashville, Tennessee; Pharmaceutical Sciences Research Center, Lipscomb University, Nashville, Tennessee (T.D., W.S.A); and Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.) bjorn.knollmann@vanderbilt.edu jeffrey.n.johnston@vanderbilt.edu scott.akers@lipscomb.edu.
Bjorn C KnollmannDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (D.J.B., J.S., B.C.K.); Departments of Chemistry (A.N.S., J.N.J.) and Pharmacology (A.G., W.S.A), and Vanderbilt Institute of Chemical Biology (A.N.S., J.N.J.), Vanderbilt University, Nashville, Tennessee; Pharmaceutical Sciences Research Center, Lipscomb University, Nashville, Tennessee (T.D., W.S.A); and Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.).ORCID 0000-0003-4956-9735
Nebraska Medical Center · US
Funding
Toward a Mechanism-Based Approach to Treating Cardiac ArrhythmiaR35HL144980 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KNOLLMANN, BJORN C · 2019 to 2025
$7.1MDevelopment of a Mirror-Image Natural Product as an Antiarrhythmic TherapeuticR01HL151223 · NHLBI · VANDERBILT UNIVERSITY · PI JOHNSTON, JEFFREY NICHOLAS · 2020 to 2023
$3.1MDevelopment of Ryanodine Receptor 2 Selective ProbesF31HL151125 · NHLBI · VANDERBILT UNIVERSITY · PI SMITH, ABIGAIL · 2020 to 2021
$53kNHLBI NIH HHS F31 HL151125NHLBI NIH HHS R01 HL151223NHLBI NIH HHS R35 HL144980
Abstract
The unnatural verticilide enantiomer (
Indexed as
Ryanodine Receptor Calcium Release ChannelTachycardia, VentricularAnimalsAnti-Arrhythmia AgentsArrhythmias, CardiacDepsipeptidesMiceMyocytes, CardiacAnti-Arrhythmia AgentsDepsipeptidesRyanodine Receptor Calcium Release Channelverticilide
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.